Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Down 50.0% in May

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the target of a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 39,619 shares, a decrease of 50.0% from the May 14th total of 79,267 shares. Based on an average daily volume of 84,492 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

OTSKY has been the subject of several research analyst reports. The Goldman Sachs Group lowered shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Otsuka Stock Performance

Shares of Otsuka stock opened at $32.06 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The stock has a market capitalization of $34.44 billion and a price-to-earnings ratio of 13.53. The business has a 50-day moving average of $34.68 and a 200 day moving average of $32.28. Otsuka has a 12 month low of $21.68 and a 12 month high of $37.52.

Otsuka (OTCMKTS:OTSKY) last announced its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, sell-side analysts forecast that Otsuka will post 1.99 earnings per share for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.